The Bean Story

"I ate beans for lunch and now I have this terrible back pain! "

As an anecdote, I'd say, 85% of patients in my clinic with pain in the back, limbs and joints, blame beans and its relatives - peanuts, mongo, the like-  for the predicament. Somehow, embedded in the minds of many is this notion that arthritis is one and the same, what ever body part gets painful and swollen, and that beans do it.

Truth is, there are a hundred or so conditions that cause pain in the back, limbs, and joints. One of these, is the Gout. This arthritis can be precipitated by food, -not just food, but inordinately large amounts of red meat, alcohol and beer, small fishes and shellfish and internal organs, in susceptible individuals - the obese, those with family history of gout and mostly, the male gender.
Where's the beans?  Not in this new list published in 2010.

There is a small catch though. In the Philippines, high salt content in the diet, plus, the way we eat our mongo and peanuts (by the spoonful and bowl), may still be responsible for these acute attacks of painful toes, (podagra) that come after a night of beer drinking (with bowls of peanuts on the side). Never mind the steamed crabs and tiger prawns sauteed in ginger and coconut milk!

After decades of untreated gout, this may happen. So, careful....

                                                                      photo borrowed with permission from the

Section of Rheumatology

UP-PGH

The Bone and Joint Decade 2010 and Beyond

The Bone and Joint Decades : 2010 and Beyond - an Unfinished Business

Ester Z. Gonzales-Penserga, MD

(Lecture given on the occasion of the 2010 Philippine Orthopedic Society Annual Meeting)

The Bone and Joint Decade (BJD) is a global movement,  proclaimed by the World Health Organization declaring that the first ten years of the 21^st century be directed at bringing awareness to bone and joint diseases, their effects on the individual and society and to encourage research in the field, aiming at the widest spectrum of issues, from medical education, lay and patient concerns on treatment, self help programs and advocacy. All sectors of society, including government was encouraged to adapt and participate through voluntary and innovative efforts to bring BJD goals to reality in the unique settings of each nation and its people.

The Philippines responded to the call, with five specialty organizations, namely, the Philippine Rheumatology Association, Philippine Association of Rehabilitation Medicine, Arthritis Foundation, Osteoporosis Society of the Philippines Foundation, Inc. and the Philippine Orthopedic Association,  forming the Philippine Council for the Bone and Joint Decade (PCBJD) in the year 2000. The collective work resulted in the Philippine government’s recognition of the BJD on July 5, 2004 through Presidential Proclamation 657 declaring the Bone and Joint Decade in the Philippines. It became the 54th government worldwide to recognize the BJD initiative.

 The PCBJD started yearly nationwide awareness programs since its inception in 2000. Major cities in the country – Iloilo, Bacolod, Davao, Cebu and Cagayan de Oro City soon actively initiated public awareness campaigns with mass media and local government participation. The In-office Exercise program, 3pm Banat Buto, a major output, was introduced to big government and private offices for integration into their health programs. The PCBJD, likewise, got involved in launching the Road Trauma Prevention program, which was presented to the Metro Manila Development Authority. In these different projects, patient groups and pharmaceutical companies helped. The PCBJD was likewise represented in international meetings of the BJD, together with patient representatives. Abroad, similar projects materialized, notably, educational materials of Japan using the “manga” comics concept, the Netherlands’ project on improving medical curriculum on the diseases, Canada’s on line programs on exercises, among others. More than 100 governments worldwide have declared the BJD in their respective countries.

 2010 marks the last year of the first decade of the BJD. For all the good intentions and the cohesive work done by the PCBJD, we see so much work still needs to be done, and issues to be pursued. Similar to other member countries, including developed nations, engagement with government should be optimized. The Philippine public health priority still hinges on infectious diseases, cardiovascular diseases and cancer. Muskuloskeletal diseases rank low in priority. Sustaining the programs that have been started, finding funds with which to embark on landmark researches on musculoskeletal diseases, are among the unfinished work. Despite these odds, we in the PCBJD will present and turn over to the next generation of advocates these programs to pursue, and build upon, so that the Filipino patient with bone and joint diseases can be fully managed and served.

EULAR Conference in London

The 2011 EULAR Congress in London proved to be a balanced meeting, with schedules easy to handle, and topics quite balanced. Osteoarthritis was discussed at length, with some new insights, while rheumatoid arthritis still got the top billing.

EULAR in London

May 25-28, 2011 is EULAR (European League of Associations for Rheumatology) Congress in London. More commentaries in a day or 2. I hope that balanced treatment of topics will make this trip worthwhile - balanced, as in, discussions of new inflammatory entities- MAS and other rare birds, etc... and less of the relooped RA topics! - But London by itself makes the 15+ hour trip worthwhile already.

Readers may want to know that there are many arthritis meetings worldwide, one being the EULAR.
There is the APLAR (Asia-Pacific...), ACR (American College of Rheumatology), OARSI (Osteoarthritis Research International), now also known World COngress of Osteoarthritis, Lupus International, Osteoporosis,.... and other regional and almost always individual countries have their own arthritis meetings.

Maximizing Treatment for Osteoarthritis: A 3 Part Story (2011 Abstract of Lecture)

Treatment of Osteoarthritis remains a challenge, and reviewing data from the mid 1990’s to present, the advances in understanding the disease have not been matched with advances in treatment,  compared to that seen in rheumatoid arthritis, for instance.

This symposium has 3 parts, namely, new concepts in pathogenesis and pathology that has fueled research in targeted therapy, use of OA treatment guidelines and the future of OA treatment.

Part 1: Osteoarthritis as a disease is a heterogenous entity, with incongruence in its anatomic, radiographic and clinical characteristics. Osteoarthritis in the spine, hands, hips and knees can be different diseases, with different risk factors and remain radiographic entities for extended periods before they manifest clinically as pain. Pain is generated by various mechanisms, the recent concept being, bone marrow lesions (BMLs) that are consistent anatomically with pain and progression of cartilage disease. Inflammatory elements are established in synovium, subchondral bone and periarticular fat pad, triggering studies on new targets of treatment.

Part 2: Treatment has focused on pain control and prevention of disability. Clinical practice guidelines abound, by specialty, country, by advocacy. Adherence to these expensive projects is in question. Western data show low adherence to recommendations on exercise and weight loss, and instead, drug prescription and surgery are resorted to more often than necessary. Non-pharmacologic treatment remains by evidence, the first line treatment for the control of pain and for preserving function. Drug treatment starts with analgesics. The GAIT study shows a rather big placebo effect for OA pain and the effects of many of drugs are small over that of placebo.

Part 3: Targeted treatment and newer approach to control pain and preserve function continue to be explored. Disease modifying OA drugs have long been in the market with inconsistent evidence. Diacerein, avocado unsaponifiables, chondroitin sulphate, glucosamine salts have known anti- metalloproteinase and anti -cytokine effects. The clinical effects of disease modification are difficult to measure. Current studies on monoclonal antibodies are promising for the control of pain, but again, these modalities would suffer from cost considerations.

In summary, treatment for OA can be maximized by considering the patient as a whole, keeping them functional and pain free, in the safest way possible. For now, clinical practice guidelines contain recommendations that have been judiciously studied for evidence of efficacy and safety and should therefore help the clinician achieve the objectives of treatment.

Arthritis IQ

Only 2 took the test....
Hmmmmm....

Arthritis IQ: what do you know about arthritis? (answers next posting)

1. When I have pain in the muscles and joints, I should refrain from eating legumes and fish sauces, meat, etc.
       True
       False
2. Pain in the legs and feet in young adults can be due to:
       A. beer binge last night
       B. poorly fitting shoes
       C. unusually long walks (in the mall... or some field work) )or travel
       D. something I inherited from my parents
3. When my shoulders and back are painful, I should have a back massage.
      True
      False
4. Which infections can also present with arthritis?
      A. hepatitis
      B. HIV
      C. influenza (flu)
      D. all of the above
5. Diabetes is a common disease that can have rheumatism as common symptom.
      True
      False